Molecular Matrix, Inc.

Molecular Matrix, Inc. is a biotechnology company based in West Sacramento, California, that specializes in osteobiologic technologies and tissue regeneration solutions, particularly for bone regeneration. Founded in 2011 as a startup from UC Davis, the company has developed a synthetic hyper-crosslinked carbohydrate polymer (HCCP) platform for tissue engineering applications. The flagship product, Osteo-P® Bone Graft Substitute (BGS), is designed for orthopedic surgery to enhance bone tissue regeneration. It has received FDA 510(k) clearance and has shown positive clinical outcomes since its launch in 2018. In addition to bone regeneration, Molecular Matrix offers advanced research tools for stem cell cultivation, including the GroCell-3D™ product portfolio, which features 3D scaffolds and a dynamic cell culture system. Molecular Matrix, Inc. aims to accelerate healing and restore mobility through innovative solutions in regenerative medicine. The company serves customers in the biomedical and biotechnology sectors, including orthopedic surgeons and researchers focused on tissue engineering and regenerative medicine.

• Employees 29
• Founded 2011
• Annual Revenue $6803000
• Total Funding $985416